论文部分内容阅读
目的:探讨YKL-40蛋白的表达与小细胞肺癌(small cell lung cancer,SCLC)临床病理特征及预后的关系。方法 :采用免疫组织化学Envision法检测105例SCLC组织和40例癌旁组织YKL-40蛋白的表达情况。结果:YKL-40在SCLC组织和癌旁组织中的阳性率分别为72.4%和22.5%,差异有统计学意义(P<0.01);YKL-40的表达与患者性别、年龄和吸烟情况无显著相关,而与临床分期、淋巴结转移有关,差异有统计学意义(P<0.05)。105例SCLC患者的中位生存期(overall survival,OS)为16.3个月;YKL-40阳性表达者中位OS为12.4个月,明显短于阴性表达者的中位OS 25.6个月,两者差异有统计学意义(P<0.05)。单因素分析显示,临床分期和YKL-40表达与预后相关;多因素分析显示YKL-40的表达可以作为SCLC的独立预后因素。结论:YKL-40蛋白可以作为一个预测SCLC患者术后复发、转移及预后的分子标记物。
Objective: To investigate the relationship between the expression of YKL-40 protein and the clinicopathological features and prognosis of small cell lung cancer (SCLC). Methods: Envision method was used to detect the expression of YKL-40 protein in 105 cases of SCLC tissues and 40 cases of adjacent tissues. Results: The positive rates of YKL-40 in SCLC tissues and paracancerous tissues were 72.4% and 22.5%, respectively, with significant difference (P <0.01). The expression of YKL-40 had no significant correlation with the gender, age and smoking status Related, and with clinical stage, lymph node metastasis, the difference was statistically significant (P <0.05). The overall survival (OS) of 105 patients with SCLC was 16.3 months; the median OS was 12.4 months in patients with YKL-40 positive expression, which was significantly shorter than the median OS of negative expression patients by 25.6 months, both The difference was statistically significant (P <0.05). Univariate analysis showed that clinical stage and YKL-40 expression correlated with prognosis. Multivariate analysis showed that YKL-40 expression could be an independent prognostic factor in SCLC. Conclusion: YKL-40 protein can be used as a molecular marker to predict the recurrence, metastasis and prognosis of SCLC patients.